Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: LHSIF) announced this morning that the company is doubling its cultivation capacity at its Liberty Health Sciences 360 Innovation Campus in Florida. The company is increasing its production capacity in conjunction with the growing demand in the state of Florida for medicinal cannabis.
The planned expansion will increase capacity by 20,000 sq. ft. which brings the total cultivation capacity of the facility to 41,200 sq. ft. Eventually when their Phase 2 expansion is complete on the campus, Liberty Health Sciences plans to have a total of 80,000 sq. ft. available for the cultivation of medicinal cannabis. The facility is operational and currently utilizes high-tech irrigation systems, grow lighting, air filtration machines, and temperature controlled systems to ensure consistency with their product.
The Liberty Health Sciences 360 Innovation Campus will offer a 24 hour state wide delivery service with real time updated delivery information for their customers. Their delivery services will be provided across the state of Florida.
George Scorsis, CEO of Liberty Health Sciences gave this statement in the press release:
“Liberty’s commitment to provide all Florida residents with convenient access to the best cannabis products and some of the industry’s best educational resources starts with the expansion of our Cannabis Education Centers and new and exciting initiatives. We will continue to expand and upgrade our production line and find resourceful ways to supply all Florida residents with convenient access.”
You may be interested
Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio OregonEditor - November 27, 2018
Vancouver, BC -- (November 27, 2018) -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) and its joint venture…
Wayland Group Enters UK Cannabis Market with Theros Pharma AcquisitionEditor - November 26, 2018
Wayland Group (CSE:WAYL) (OTCQB:MRRCF) has announced this morning that their company has entered into an agreement to acquire 51% of UK company Theros Pharma Ltd. The Wayland Group…
GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical TrialsEditor - November 26, 2018
GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®.…